The Phase II STARLIGHT study (NCT05417126) found that a single intravitreal injection of gene-agnostic MCO-010 in six ...

CytomX's Phase I trial of ADC CX-2051 in colorectal cancer will continue based on a decision made by a safety committee ...

According to the US Centers for Disease Control and Prevention, substance use disorder (SUD) affects approximately one in six ...

Remegen's Telitacicept met its primary endpoints in a Chinese trial, while a US-based Phase III trial in Sjögren's syndrome ...

Elicio's mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key ...

Schrödinger said it is ending development of the CHC7 inhibitor in blood cancer as both a monotherapy and combination.

Aligos has initiated dosing in the Phase II B-SUPREME trial of its ALG-000184 in people with chronic hepatitis B virus (HBV) ...

Vendanta's CEO also announced the company is cutting 20% of its workforce as a result of the Phase II UC trial failure.

CuraCell Holding’s CTA has received approval from Germany's Paul-Ehrlich-Institut (PEI) to begin a Phase I/IIa trial of CC-38 ...

Stoke Therapeutics and Biogen have dosed the first subject in the Phase III EMPEROR trial of zorevunersen for Dravet syndrome ...

Marea Therapeutics has enrolled the first subject in the MAR-201 Phase I trial of MAR002, aimed at treating acromegaly.

In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.